Category Archives: News and Events

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting
March 26, 2019

• Early data of BriaCell’s combination study of lead candidate, Bria-IMT™, with KEYTRUDA® (by Merck ...

BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement
March 25, 2019

BERKELEY, Calif., and VANCOUVER, British Columbia, March 25, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering
March 20, 2019

BERKELEY, Calif., and VANCOUVER, British Columbia, March 20, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Welcomes BioPharma Industry Experts to its Board of Directors
March 18, 2019

BERKELEY, Calif., and VANCOUVER, British Columbia, March 18, 2019 – BriaCell® Therapeutics Corp. (“BriaCell®” or ...

BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire
March 7, 2019

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) — via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire ...

BriaCell Announces C$500,000 Equity Investment by BriaCell Director
February 26, 2019

BERKELEY, Calif., and VANCOUVER, British Columbia, February 26, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences
February 19, 2019

· New insights into BriaDX™, BriaCell’s simple patient HLA-type identification test, will be presented at ...

BriaCell Appoints Jamieson Bondarenko to its Board of Directors
February 12, 2019

BERKELEY, Calif., and VANCOUVER, British Columbia, February 12, 2019 – BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ...

BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference
January 2, 2019

· Completed development of a novel frozen formulation of Bria-IMT™ for on-demand shipment to clinical ...

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference
December 6, 2018

· Interim data indicate an excellent safety profile for the combination regimen in advanced breast ...

Skip to content